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were evaluated based on US and European PRO/HRQOL guidance criteria.RESULTS:
The review identified 8 HRQOL measures used with EB patients: 3 generic (SF-36;
EQ-5D, EQ-5DY); 4 dermatology-specific (DLQI, CDLQI, DQOLS, Skindex); and 1 EB-
specific (QOLEB). Only the CDLQI and QOLEB were specifically designed for pediat-
ric populations (ages 4-16 and 10 years, respectively). The QOLEB was the only
instrument for which content was derived from EB patients; 26 patient interviews
were conducted, of which 9 were with patients 18 years. Despite pediatric input
during development, not all QOLEB content is relevant to children/adolescents;
items assessing family and financial impact are not appropriate for these respon-
dents. Psychometric properties have been established among pediatric EB patients
only for the QOLEB (convergent validity [DLQI: R  0.774]; internal consistency [
0.931]; test-retest reliability [R  0.843]). CONCLUSIONS: Few published measures
meet current regulatory standards for HRQOL evaluation in pediatric EB patients.
Given the age range for EB, an HRQOL instrument that evaluates age-appropriate
concepts was not identified. Further research is needed to document and assess
HRQOL concepts in pediatric patients with EB.
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OBJECTIVES:To compare the rate and cost of traditional versus on line recruitment
methods to medical surveys in 2 different patient populations. METHODS: We
compared traditional to on line advertising in 2 separate projects (conducted in the
UK) across the same time period using the same internet and social media recruit-
ment methodologies allowing a comparison of the costs and effectiveness. By look-
ing at 2 quite distinct populations – the first being cholesterol lowering agents, thus
an older age with cardiovascular disease and the second women with problem
periods, hence a younger and otherwise healthy group we could evaluate the re-
cruitment methods. RESULTS: All costs are direct payments and exclude labour;
Cholesterol lowering agents; Traditional methods – recruitment through chain of
pharmacists using leaflets; 303 patients recruited over 9 months; cost/ survey £3.94.
Internet/Social media – adverts placed on facebook.com, google and third party ad
network; 3812 visitors to website; cost/ visitor £0.23; 572 survey completions over 11
weeks; cost/ survey £1.53. Problem Periods: Traditional methods – magazine ad-
verts, exhibition stand, press releases; 232 Women recruited over 8 weeks; Cost/
survey £18; Internet/Social Media; 6000 visitors to website over 11 weeks; cost/
visitor £0.30; 1534 survey completions over 11 weeks; cost/ survey £1.51.
CONCLUSIONS: Whilst traditional methods of recruiting participants were suc-
cessful, they were generally slower and cost more per person recruited. Internet
advertising and use of social media sites offers the potential of rapid, cost effective
recruitment. This result however does not tell us if the traditional adverts were
making it more likely people would search on line, thus driving the on line recruit-
ment or if the statins population (our statin population mean age was 62) is repre-
sentative of older age groups where it is anticipated that more traditional adver-
tising would be required.
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OBJECTIVES: The MFSAF Diary is a refined version of the Myeloproliferative Neo-
plasm Symptom Assessment Form (MPN-SAF) designed to measure the impact of
MF-related symptoms. Six symptoms are rated on a scale from 0 (absent) to 10
(worst imaginable): 1) night sweats; 2) itching (pruritus); (3) abdominal discomfort;
4) filling up quickly when you eat (early satiety); 5) pain under ribs on left side; and
6) bone or muscle pain. The objective of this study is to present the development of
a generic Spanish version to be used in Mexico, Spain, and the USA. METHODS: 1)
Concept definition; 2) Development of a Spanish translation in Mexico, Spain, and
the USA; 3) Creation of a reconciled Spanish version using the three Spanish ver-
sions as a basis; 4) Backward translation of the reconciled version; 5) Cognitive
interviews with five patients in each country. RESULTS: The development of the
reconciled version did not show major difficulties. For instance, “bone or muscle
pain” was translated as “dolor en los huesos o músculos,” and well understood by
patients. It was agreed that the use of nouns (huesos/musculos for bones/muscles)
was more appropriate as people with a very low education level might have diffi-
culties to understand adjectives such as “óseo” (osseous). Patients had difficulties
with “itching (pruritus)” translated at first by “comezón/prurito/picor.” It was im-
possible to find a common term for the three countries, and a compromise was
found with the use of the association of “comezón/picor,” with “comezón” widely
used in Mexico and “picor” in Spain. “Prurito” could not be chosen for all countries
since it was problematic for Spanish patients. CONCLUSIONS: The creation of a
generic Spanish version of the MFSAF Diary was made possible by developing
Spanish versions in Mexico, Spain, and the USA, and accepting compromises when
common terms could not be used.
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OBJECTIVES: The Repeatable Battery for the Assessment of Neuropsychological
Status (RBANS) was initially developed as a neuropsychological screening tool for
dementia. It is now commonly used to screen for abnormal cognitive decline across
a range of clinical populations. The Picture Naming subtest, a confrontation-nam-
ing task requiring subjects to name 10 line drawings, is used to assess basic verbal
functions and language skills. This abstract presents the challenges faced during
the translation of 40 pictured words into 13 languages (Bulgarian, Chinese for Tai-
wan, Czech, English and French for Canada, German, Hindi, Hungarian, Kannada,
Korean, Marathi, and Spanish for Mexico and the USA).METHODS: In each country,
a thorough forward translation was performed including two translators and a
speech therapist, all native speakers of the target languages. Criteria for selecting
substitute items were developed in instances where literal translations would be
culturally inappropriate (i.e., substitutes should match the frequency of use of the
source terms, belong to the same semantic field, be familiar to all people and easily
drawn). Finally, a clinician’s review was performed. RESULTS: Eleven of the 40
source words had to be substituted. The languages that required the most substi-
tutions were Bulgarian, Chinese, Hindi, Hungarian, Kannada, Korean, and Marathi,
whereas few substitutions were needed for languages culturally close to US English
(Canadian English and French, German, and US Spanish). The most culturally prob-
lematic picture words were “Barn” and “Toboggan/Sled.” “Barn”, for example, was
replaced by the word “House” and its corresponding picture in eight out of the 13
languages. CONCLUSIONS: This project demonstrates that translating pictured
words meaningfully in a clinical research context requires the collaboration of the
developer to correctly interpret the original, translators for their knowledge of
language, a speech therapist for his/her understanding of the word’s function, and
a clinician to validate the chosen word’s relevance.
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OBJECTIVES: Multiple sclerosis (MS) is the most common disabling neurological
disease of young adults and is associated with significant economic and Health-
Related Quality-of-Life burden. Cost-effectiveness models in MS are commonly
structured on health states reflecting progressing disease severity, represented by
scores on the Expanded Disability Status Scale (EDSS) 0-9, whereby single utility
and cost values are applied to each EDSS state in the model. Using EQ5D-5L results
from an Irish outpatient cohort of 212 patients with MS, the aim of this study was
to model the relationship between utility and EDSS. METHODS: The association
between disease severity and quality of life in MS was determined using a piece-
wise linear regression where EDSS scores were treated as discrete indicator vari-
ables. The model was fitted in WinBUGs; with the constraint that increasing EDSS
score is associated with a disimprovement in quality of life. The mapping between
utility and EDSS can be determined from these data. RESULTS: Disease severity
(EDSS) had a significant negative impact on HRQoL (p0.001). A non-linear decline
in utility was observed with the most dramatic declines occurring once patients
reach EDSS 6 and beyond. Mean utility values from the piecewise linear regression
ranged from 0.88 (EDSS 0) to 0.22 (EDSS 9), and were associated with smaller
standard errors than a simple linear model. The greatest utility decrease was be-
tween EDSS 6 and 7 (0.15) and EDSS 7 and 8 (0.41). CONCLUSIONS: The decline
in HRQoL in MS is multifactorial, but can be explained primarily by the severity of
the disease. The application of one linear model to the data was not justified. The
piecewise regression improved model efficiency and reduced sampling variability
by utilising the trends in utility decline between EDSS states.
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OBJECTIVES: To explore how patients and payers perceive value and risk and
investigate the role of patient-reported outcomes.METHODS:Quintiles surveyed a
variety of US and UK stakeholders including: an online survey of payers (US man-
aged care, UK National Health Service) and a telephone survey of adult patients
being treated for a chronic disease.RESULTS:Between January and March 2012, 144
payers (75 US, 72 UK National) and 1009 patients (509 US and 500 UK) were sur-
veyed. In general, payers were more optimistic that the quality of health care
would be improved 10 years from now than patients (68% US / 66% UK payers vs.
49% US / 38% UK patients). From the payer perspective, over 80% of payers support
use of risk sharing for: 1) population-based performance guarantees (i.e., coverage
dependent on meeting a benefit target) and 2) Coverage with Evidence Develop-
ment (CED) deals (i.e., future review based on real-world product evidence). High
administration costs (66%), difficulties in agreeing on definition of success (67%),
and difficulties in accurately measuring treatment success (63%) are among main
problems. With 77% of US and 73% UK payers supporting the shift to a more pa-
tient-oriented approach to treatment assessment, it is not surprising that PROs are
the metric most commonly used to assess risk/benefit (60% and 71% respectively).
Patients are in agreement with payers that PROs are most important in how they
evaluate the value of medicines (51% US, 60% UK). Other important drivers of
patient value: helping people live longer (14% US, 24% UK) and affordability (25%
US, 2% UK). CONCLUSIONS: Payers and patients agree that use of PRO data is
critical to assessing value and benefit-risk for prescription medicines. The shift to
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